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Abstract
Background: Gliomas are the most common and aggressive primary brain tumors for which unfortunately no effective
treatment modalities exist despite advances in molecular biology as the knowledge base to unravel the extremely
complex molecular mechanisms of tumorigenesis is limited. In this study an attempt has been made to understand the
molecular pathological basis of tumorigenesis which led to an identification of an oncogene, CDC2, and an epigenetic
strategy has been evaluated to control the tumorigensis by downregulating this oncogene.
Methods: Tissue microarrays were utilized to investigate the expression of genes in a large number of tumor samples
and to identify overexpressed genes which could be potentially causing tumorigenesis. Retroviral vectors expressing
short hairpin RNAs (shRNAs) targeted against CDC2 were designed and transducted into human glioma cell line ex vivo
in order to downregulate the expression of CDC2. Real-Time PCR was used to determine the level of CDC2 mRNA.
Western Blotting was used to determine the level of expression of CDC2 protein as measure to quantify down
regulation of CDC2 expression along with use of flow cytometry to investigate effect of shRNAs on cell cycles and
detection of apoptosis. Following ex vivo study, viral particles containing small interfering RNA for CDC2 were
subsequently injected into xenogeneic graft tumor of nude mice and the weight of human glioma xenografts, survival and
resulting phenotypic changes of target gene were investigated.
Results: Human glioma tissue microarrays indicated the positive expression rates of CDC2/CyclinB1 with a positive
correlation with pathologic grades (r = 0.982, r = 0.959, respectively). Retroviral vectors expressing short hairpin RNAs
(shRNAs) against CDC2 caused efficient deletion of CDC2, cellular G2/M arrest concluding in apoptosis and inhibition
of proliferation in human glioma cells U251 and SHG-44 cell lines ex vivo. And the viral particles containing small
interfering RNA for CDC2 were subsequently injected into subcutaneous and intracranial xenogeneic graft tuomrs of
nude mice. For subcutaneous tumors, injection of CDC2-shRNA retroviruses significantly decreased tumor weight and
volume compared with control. Immunohistochemistry indicated that CDC2 are negative and TUNEL are positive in
tumors treated with recombinant retrovirus. For mice implanted with intracranial gliomas, treatment of CDC2-shRNA
retroviruses increased survival times compared with control.
Conclusion: CDC2 gene plays an important role in the proliferation of human gliomas. Downregulation of CDC2 could
potentialy inhibit human gliomas cells growth ex vivo and in vivo. From these results, it was suggested that CDC2 might
be a potential target on gene therapy of human gliomas.
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Background
Abnormalities in cell cycle regulation are reported to be
strongly associated with tumorigenesis and progression of
tumors. The cell cycle is a complex process with myriad
genes involved and elaborate and complex signaling
mechanisms to allow for this critical cellular process. In
eukaryotes, the entry into mitosis is regulated by the acti-
vation of CDC2/Cyclin B1 complex (M-phase promoting
factor, MPF). CDC2 is known as an active sub-unit of the
MPF. It is inhibited by Cyclin-dependent kinase inhibitors
(CKI). Appropriate regulation of CDC2 is essential for the
entry into mitosis. Increasingly numerous results have
demonstrated overexpression of CDC2/Cyclin B1 in vari-
ous tumors however there is still no report of CDC2/Cyc-
lin B1 expression in clinical samples from patients with
gliomas.
In the present study, we investigated the relationship of
gene expression profiles with malignant progression of
human glioma. Tissue microarrays (TMAs) including I–IV
grade clinical glioma samples was used to determine the
prognostic effect of the CDC2/Cyclin B1 expression in
gliomas on different grades. To reveal the roles of CDC2/
Cyclin B1 in human malignant gliomas, CDC2 in glioma
cell line, it was down-regulated by retrovirus vectors
expressing short hairpin RNAs (shRNAs) ex vivo and in
vivo.
Methods
Clinical information
Tumor specimens were obtained with informed consent
from a 37-year-old female patient who underwent initial
surgical removal in January 1999 and subsequent recur-
rent resections of a right temporal tumor July 1999 and
February 2001 at the 2nd Affiliated Hospital of Soochow
University (Suzhou, China) and did not receive chemo-
therapy and radiation between these stages of progres-
sion. The tumor was diagnosed as ganglioglioma (WHO
grade I), anaplastic astrocytoma (WHO grade III) and
glioblastoma (WHO grade IV) on paraffin embedded sec-
tions (Figure 1). Normal brain tissues were obtained from
the same patient when she was undergoing partial
removal of the right occipital lobe for cerebral decompres-
sion. Part of the fresh tissue was used for initiation of tis-
sue culture and the remaining part was snap frozen in
liquid nitrogen and stored at -80°C for subsequent molec-
ular cytogenetic analysis.
Cell Culture
Human glioma cell line SHG-44 (P53 mut) was derived
from a poorly differentiated astrocytoma of the left frontal
lobe of a 32-year-old woman who was undergoing surgi-
cal removal of a right temporal tumor at the Department
of Neurosurgery, the 2nd Affiliated Hospital of Soochow
University School of Medical (Suzhou, China). It was the
first established human glioma cell line in China accord-
ing to the library and information system of the Chinese
Academy of Sciences, and has been widely used in human
glioma research in China [1-3]. Human glioma cell line
U251 (P53 mut) was obtained from the Institute of Bio-
chemistry and Cell Biology, Shanghai Institutes for Bio-
logical Sciences, Chinese Academy of Sciences (Shanghai,
China). Phoenix cells were the gift from Dr. Gu JM (Van-
derbilt University, Nashville, Tennessee). All cell lines
were cultured in Dulbecco's Modified Eagle Medium (Inv-
itrogen, California, U.S.) supplemented by 10% heat-
inactivated fetal calf serum (Si Ji Qing, Hangzhou, China).
Culture of Brain tumor stem cell spheres, neural stem cell 
spheres and multicellular tumor spheres
Human glioma tissues were obtained from a 52-year-old
female patient who underwent two operations within 2
months for rapid relapse of human malignant gliomas.
Both primary and recurrent lesions were pathologically
diagnosed as mixed glioma consisting of anaplastic epend-
ymoma and astrocytoma. Human fetal brain tissue was
Clinical information of 37-year-old female patient Figure 1
Clinical information of 37-year-old female patient. A, Brain 
enhanced CT scan demonstrated an irregularly enhanced 
tumor node with cyst in right temporal lobe. B showed 1st 
recurrence tumor relapsed and invaded posteriorly, superi-
orly to parietal lobe. C showed 2nd recurrence tumor was 
solid lesion with obvious enhancement. D, primary tumor 
(HE staining, magnification 400×): neoplastic neurons, neo-
plastic astrocytes and binucleate neurons (↑) can be seen. 
Pathological diagnosis was ganglioglioma (WHO grade II). E, 
1st recurrent tumor (HE staining, magnification 400×): 
Neop1astic neurons disappeared, while neoplastic glial cells 
increased with high density. Nuclei heteromorphism can be 
seen and chromatin increased obviously. Pathological diagno-
sis was anaplastic astrocytoma (WHO grade III). F, 2nd 
recurrent tumor (HE staining, magnification 100×): Micro-
scopic field was crowded with neoplastic astrocytes. And 
pseudopalisade formation and multinucleated giant cells were 
found. Pathological diagnosis was glioblastoma multiform 
(WHO grade IV).BMC Cancer 2008, 8:29 http://www.biomedcentral.com/1471-2407/8/29
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obtained from consent-informed women who received
induced abortion in accordance with the protocol
approved by Ethical guidelines for the use of human
embryonic or fetal tissue for experimental and clinical neu-
rotransplantation and research of Network of European
CNS Transplantation and Restoration (NECTAR) [4].
The fresh tumor specimens was washed, deprived of ves-
sels, acutely dissociated in oxygenated artificial cerebros-
pinal fluid and subjected to enzymatic dissociation as
described previously [5]. Tumor cells were then re-sus-
pended in serum-free DMEM/F-12 containing human
recombinant N2, EGF and bFGF (20 ng/ml; Invitrogen,
California, U.S.), and plated at a density of 3 × 106 live
cells/60-mm plate. Cells were fed by changing half of the
medium every 3 days. Brain tissue from a 1-month-old
abortive dead embryo was subjected to the same proce-
dure as described above to get neural stem cell spheres [6].
SHG44 and U251 cells were planted in liquid media over
an agar base to form multicellular tumor spheres [7].
Construction of tissue microarray and 
Immunohistochemical analysis
A total of 71 gliomas of the cerebral hemisphere, resected
at the 1st and 2nd affiliated Hospital of Soochow Univer-
sity were studied. These tumors were from 40 men and 31
women, ranging in age from 4 to 80 (mean, 41.04) years
at diagnosis. All of these patients did not receive chemo-
therapy and radiation before surgical removal. Tumors
were classified and graded using the World Health Organ-
ization (WHO) scheme (2000) (grades I–IV) [8]. Eleven
normal brain tissues were gathered from consent-
informed individuals who underwent partial removal of
the temporal lobe for cerebral decompression. SHG44
multicellular tumor spheres (n = 4), GBM multicellular
tumor spheres (n = 4), brain tumor stem cell spheres (n =
4) and neural stem cell spheres (n = 4) were centrifuged
and embedded in melted 3% agarose gel to form agarose
cell blocks (ACBs) [9]. Tissue microarray (TMA) technique
was used for immunohistochemical study [10]. The
tumor samples and cell blocks were fixed in 4% phos-
phate buffered formaldehyde and processed into paraffin
blocks with standard methods. Histologically representa-
tive tumor regions of hematoxylin-eosin (HE) stained
slides were selected by a neuropathologist (Professor Liu
zhen yan) and corresponding areas were sampled in tissue
microarray blocks with the aid of manual tissue microar-
rayer (Bo Nan Biotechnology Inc. Shanghai, China)
according to the manufacturer's instruction. The sample
diameter of the tissue core in the microarray block was
600 μm.
Tissue microarray sections were washed in PBS and incu-
bated for 1 h with rabbit anti CDC2 polyclonal antibody
(Santa Cruz Biotechnology), rabbit anti CyclinB1 polyclo-
nal antibody (Santa Cruz Biotechnology) or with 1% BSA-
PBS as a negative control. After washing, the slides were
incubated with biotinylated anti-rabitt immunoglobulin
(LSAB) for 30 min, washed again, and incubated with
horseradish peroxidase-conjugated streptavidin for 30
min. The reaction was revealed by 3, 3'-diaminobenzidine
and counterstained with hematoxylin.
Evaluation of slides
Antigen expression was defined as the presence of nuclear
staining on tumor cells for CDC2, CyclinB1 and TUNEL.
An immunoreactive score (IRS) was applied. The IRS
(negative (-), 0~2; weak positive (+), 3~4; positive (++),
5~6; strong positive (+++), >7) was the product of staining
intensity (graded between 0 and 3) and the percentage of
positive cells (graded between 0 and 4: 0, ≤5%; 1,
6%~25%; 2, 26%~50%; 3, 51%~75%; 4, ≥75%) [11]. Five
vital tumor fields were evaluated (magnifications 400×)
and a final mean score for each tumor was achieved.
Construction of recombinant retroviral vectors expressing 
short hairpin RNAs and transfection in vitro
The pSUPER.retro.puro purchased from OligoEngine was
a vector system for expression of short interfering RNA.
Recombinant retroviral vectors expressing short hairpin
RNAs were constructed according to the product manual.
Three pairs of oligonucleotides were designed. The
shRNA1, 3 corresponds to positions 256–274, 789–807
of the CDC2 open reading frame, respectively. The oligo-
engine workstation software gives the effect target corre-
sponds to positions 908 of the CDC2 open reading
frame. But we designed C4 target corresponds to posi-
tions 909 (909–927). We want to know whether it was an
"inactive target" (Figure 2). These forward and reverse oli-
gos were annealed and cloned into the vector between the
unique BglII and HindIII enzyme sites. The presence of
the correct insert of recombinant pSUPER.retro vectors
(C1, C3, C4) were confirmed by sequencing (BIO BASIC
Inc, Shanghai, China; Sequencing primer 5'-GGA AGC
CTT GGC TTT TG-3').
Glioma cell lines were transfected with recombinant retro-
viral vectors using a modified Lipofectamine™ 2000 pro-
tocol (Invitrogen, California, U.S.), in which the quantity
of plasmid DNA was double of the recommended quan-
tity in order to achieve the highest transfection efficiency.
Cells were harvested 48 h after recombinant retroviral vec-
tors transfection for RT-PCR, Western blots, cell cycle
analysis and apoptosis analysis.
Cell proliferation assay in vitro
SHG44 and U251 cells were plated in 24-well plates
(Corning, NY, U.S.A) at 1.5 × 105 per well. Twenty four
hours after transfection, cells were transferred into a 50 ml
cell culture flask (Corning). Time kinetics of cell prolifer-BMC Cancer 2008, 8:29 http://www.biomedcentral.com/1471-2407/8/29
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ation was conducted at 24, 48, 72 and 96 h after transfec-
tion with recombinant retroviral vectors. Cells were
harvested with 0.25% trypsin, 1 mM EDTA in phosphate
buffered saline (PBS) and stained with Trypan blue. The
number of cells was counted with a microscope using a
haemacytometer.
RT-PCR and real time PCR
Total RNA was isolated from cells using TRIzol reagent
(Gibco, California, U.S.A) according to the manufac-
turer's instructions. Total RNA (5 μg) was reverse tran-
scribed using 1 μg oligodT primer with MMLV reverse-
transcriptase (Promega) in a 40 μ1 reaction volume con-
taining 1.25 mM deoxyribonucleoside triphosphate
(dNTP) at 42°C. PCR was performed using 1 μl of cDNA
in 50 μl PCR reaction buffer containing 15 pmol of each
primer, 0.1 mM dNTP, and 0.3 units Taq polymerase
(Promega). Primer sequences used and conditions of
these reactions were as follows: CDC2: sense 5'-GGT TCC
TAG TAC TGC AAT TCG-3'; antisense 5'-TTT GCC AGA
AAT TCG TTT GG-3', (94°C 1 min, 51°C 1 min, 72°C 1
min, ×30 cycles, 709 bp as PCR product), Cyclinb1:
sense5'-CAG TCA GAC CAA AAT ACC TAC TGG GT-3';
antisense 5'-ACA CCA ACC AGC TGC AGC ATC TTC TT-
3', (94°C 30 s, 54°C 30 s, 72°C 30 s ×30 cycles, 191 bp as
PCR product), β-actin (internal control): sense 5'-TCC
TGT GGC ATC CAC GAA ACT-3'; antisense 5'-GAA GCA
TTT GCG GTG GAC GAT-3'(314 bp as PCR product). The
products were electrophoresed through 2% agarose gel.
cDNA was used to perform real-time quantitative PCR
using MJ Research PTC-100 with TaKaRa Ex Taq R-PCR
Version 2.1 (TaKaRa, Da lian, China) and EvagreenTM
(Biotium, Inc., CA, U.S.A) according to product's instruc-
tion. Primer sequences are shown as follows: CDC2: sense
5'-CAG TCT TCA GGA TGT GCT TAT GC-3'; antisense 5'-
GAG GTT TTA AGT CTCTGT GAA GAA CTC-3'. β-actin:
sense 5'-AGC GAG CAT CCC CCA AAG TT-3'; antisense 5'-
GGG CAC GAA GGC TCA TCA TT-3'.
Protein extraction and western blot analysis
Cells were harvested using trypsin:EDTA and lysed in TRI-
zol reagent (Gibco). Proteins were precipitated from the
phenol-ethanol supernatant with isopropyl alcohol
obtained after precipitation of DNA with ethanol and dis-
solved in 1% SDS by pipetting. Protein concentrations in
solutions were determined using the Bradford protein
assay. PageRuler™ Prestained Protein Ladder (5 μl) (Fer-
mentas Inc. MD, U.S.A) and protein solutions containing
40  μg per lane were electrophoresed using SDS-PAGE
(15% polyacrylamide gel) and blotted onto nitrocellulose
(NC) membrane. Membranes were blocked with 5% fat-
free milk solution. Samples were probed with 1:200 dilu-
tion of a Rabbit polyclonal antibodies against CDC2
(Santa-Cruz Biotechnology, Inc., Santa Cruz) and a
1:5000 dilution of goat anti-rabbit HRP-conjugated IgG
(Hua mei Chemical Corp., China). Rabbit monoclonal
antibody against GAPDH (Affinity BioReagents, Inc.) was
used as a loading control. Bands were revealed using ECL
kit (Pu fei Chemical Corp., Shang hai, China).
Analysis of cell cycle and apoptosis
Cell viability was assessed by Trypan blue staining. Cell
cycle was analysed using a FACScan flow cytometer (Bec-
ton Dickinson). Briefly, cells were washed with PBS,
treated with RNase A, and stained with PI (Sigma). Apop-
tosis was assessed using rh Annexin V FITC Kit according
to manufacturer's instructions (Bender Medsystems). The
data were acquired using Cell Quest V.3.3 software (BD).
To detect apoptotic cells in xenogeneic graft tumors, sec-
tions were analyzed by terminal deoxynucleotidyl trans-
ferase-mediated deoxyuridine triphosphate-biotin nick
end-labeling (TUNEL) (Roche Molecular Biochemicals),
according to the manufacturer's instructions.
Viral packaging
The effective recombinant retroviral vectors were pack-
aged in Pheonix cells by standard calcium phosphate
transfection protocol [12]. Virus supernatant was col-
lected 48 hours post-transfection, filtered to remove non-
adherent cells and cellular debris, frozen in small aliquots
on dry ice, and stored at -80 C. Detection of virus titer was
refer to the methods of Short Protocols in Molecular Biol-
ogy [13].
Schematic depiction of three shRNA: Three pairs of oligonu- cleotides were designed and were synthesized by BIO BASIC  Inc (Shang Hai, China) Figure 2
Schematic depiction of three shRNA: Three pairs of oligonu-
cleotides were designed and were synthesized by BIO BASIC 
Inc (Shang Hai, China). shRNA1 corresponds to positions 
256–274 of the CDC2 open reading frame, shRNA3 to posi-
tions 789–807 and shRNA4 to positions 909–927. the fol-
lowing were the sequence of three pairs of oligonucleotides: 
Oligo 1:forward 5'-GAT CCC CGG GGT TCC TAG TAC 
TGC AAT TCA AGA GAT TGC AGT ACT AGG AAC 
CCC TTT TTA-3'; reverse5'-AGC TTA AAA AGG GGT 
TCC TAG TAC TGC AAT CTC TTG AAT TGC AGT ACT 
AGG AAC CCC GGG-3'; Oligo 3:forward 5'-GAT CCC 
CGG GCA CTC CCA ATA ATG AAT TCA AGA GAT 
TCA TTA TTG GGA GTG CCC TTT TTA-3', reverse 5'-
AGC TTA AAA AGG GCA CTC CCA ATA ATG AAT 
CTC TTG AAT TCA TTA TTG GGA GTG CCC GGG-3'; 
Oligo 4: forward 5'-GAT CCC CCT TGG ATT TGC TCT 
CGA AAT TCA AGA GAT TTC GAG AGC AAA TCC 
AAG TTT TTA-3', reverse5'-AGC TTA AAA ACT TGG 
ATT TGC TCT CGA AAT CTC TTG AAT TTC GAG AGC 
AAA TCC AAG GGG-3'.
s h R N A 1                              s h R N A 3            s h R N A 4
256-274                        789-807         909-927 
Open reading frame of CDC2 mRNA BMC Cancer 2008, 8:29 http://www.biomedcentral.com/1471-2407/8/29
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Mouse Models of Gliomas and Recombinant Retrovirus 
Injections
Nude mice with nu/nu gene from the NC strain (Fujita
Health University, Japan) were bred and maintained in
our Specific Pathogen Free Animal Care Facility. Female
mice (6- to 8-week-old) were used in this study. Subcuta-
neous injections of 5 × 106 tumor cells in 0.2 ml solution
were made into the flanks of recipient nude mice, as
described previously [14]. Eight mice were included in
control and experimental groups. When the diameter of
xenogeneic graft tumors was about ~0.5 cm, recombinant
retrovirus was directly injected into xenogeneic graft
tumors by using the following parameters: 10 μl per site,
10 μl infusion rate/min, 100 μl per one injection, injec-
tion per 3 days and total 3 times (total 300 μl). Twenty
days after the last injection, the difference of tumor
weights between control group and experimental group
was compared.
To determine if CDC2-depletion prolonged animal sur-
vival, 1 mm3 SHG44 xenogeneic graft tumor tissue was
injected into the frontal lobe of 6-week-old nude mice by
using the following parameters: 0.5-mm anterior, 2.5-mm
lateral, 2.5-mm depth. After 3 days, animals were treated
with a single intratumoral injection of PBS and recom-
binant C3 retrovirus (n = 8/group 20 μl per mice, 0.5 μl/
min infusion rate).
Statistical methods
The relationship between expression rates of CDC2 and
pathologic grades of human gliomas was analyzed with
correlation coefficient. The Spearman's Rank Correla-
tion was used to measure the correlation between CDC2
and CyclinB1 expression in gliomas. Statistical analyses
ex vivo were performed using the Student's t test. Statis-
tical analyses in vivo were performed using the Wil-
coxon signed-rank test. All the reported P-values are 2-
sided and a value of P < 0.05 was considered statistically
significant.
Statement of ethics
Research that is reported in the manuscript has been per-
formed with the approval of ethics committee of 2nd affil-
iated hospital of Soochow University. Animal studies
were approved by the Soochow University of Animal Care
and Use Committee and followed internationally recog-
nized guidelines.
Results
Expression of CDC2 in one recurrence brain tumor case
Expression of CDC2 in primary ganglioglioma (WHO
grade II) was as low as that in normal brain tissue, and
increased by 2.5 fold and 5.3 fold in the first and second
recurrence tumor respectively (Figure 3).
Expression of CDC2 and CyclinB1 in different grade brain 
tumors
In CDC2/CyclinB1 immunostaining, CDC2/CyclinB1
was expressed in the nuclei of tumor cells. Histologically,
high-grade gliomas tended to express high CDC2/
CyclinB1 protein levels than that in lower grade gliomas.
The immunoreactivity of CDC2/CyclinB1 showed appre-
ciably strong staining intensity among the high-grade
brain tumors. Statistically significant difference in CDC2
expression was observed between grade I and III, grade I
and IV, grade II and III, grade II and IV (P = 0.005, P =
0.008, P = 0.009, P = 0.020, respectively). Also, statisti-
cally significant difference in CyclinB1 expression was
observed among different grade. Furthermore, the posi-
tive expression rates of CDC2/CyclinB1 were positively
correlated with the pathologic grades (r = 0.982, r = 0.959,
respectively) (Figure 4, Table 1). Expression of CDC2/
CyclinB1 was very high in SHG44 and GBM, but was neg-
ative in brain tumor stem cell spheres and neural stem cell
spheres. The positive expression rates of CDC2 correlated
with CyclinB1 (r = 0.900, P < 0.01).
Downregulation of CDC2 with recombinant C1 or C3 
inhibits the proliferation in SHG44 and U251 cells
As CDC2 is one of the key components for the regulation
of cell proliferation, the anti-proliferative effect of recom-
binant C1 or C3 on human glioma cell lines was analysed.
Compared to control treatment with blank retroviral vec-
tor (C0) and transfection reagent oligofectamine alone
(X), transfection with recombinant C1 or C3 reduced the
number of SHG44 cells by 82%, 92% at 48 h, and 95%,
97% at 72 h, respectively. At 96 h, no SHG44 cells were
detectable with recombinant C1 or C3 treatment. How-
ever, treatment with the transfection recombinant C4 had
no effect on inhibition of proliferation in SHG44 cells.
Expression of CDC2 in one recurrence brain tumor case was  detected by RT-PCR Figure 3
Expression of CDC2 in one recurrence brain tumor case was 
detected by RT-PCR. CDC2 gradually increased with malig-
nant grade, β-actin served as an equal loading control. Nor-
mal brain tissue (lane A), primer ganglioglioma (lane B), first 
recurrence anaplastic astrocytoma (lane C), second recur-
rence glioblastoma multiform (lane D)BMC Cancer 2008, 8:29 http://www.biomedcentral.com/1471-2407/8/29
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The result indicated C4 was an "inactive target" (Figure 5).
Anti-proliferation of recombinant C1 or C3 was more
robust in U251 cells. The number of U251 cells was
reduced by 90% (C1) and 93% (C3) at 24 h, and 94%,
98% at 48 h, respectively. At 72 h, no U251 cells were
detectable with recombinant C1 or C3 treatment.
Recombinant C1 or C3 reduce mRNA and protein 
expression of CDC2 in SHG-44
Due to the tremendous anti-proliferation, we failed to
harvest enough cells to perform RT-PCR and Western blot
analysis on U251 cells, and therefore analyses were per-
formed on SHG44 cells 48 h after transfection with the
recombinant retroviral vectors to examine the effects of
the three recombinant retroviral vectors on CDC2 mRNA
and protein expression. mRNA level of CDC2 was signifi-
cantly downregulated after the transfection with recom-
binant C1 or C3 as compared to negative controls, off-
target sequence C4, the blank retroviral vector C0, and
transfection reagent alone X (Figure 6A, lanes 1, 4 and 5).
None of the recombinant retroviral vectors affected
mRNA level of Cyclin B1 (Figure 6B), suggesting that these
recombinant C1 C3, and C4 were highly specific. The real-
time PCR revealed that mRNA level of CDC2 decreased by
98.3% and 98.5% after transfection with recombinant C1
and C3, respectively (data not shown).
The protein level of CDC2 standardized to the level of
GAPDH efficiently decreased by 85% and 88% after trans-
fection with recombinant C1 or C3 (Figure 6C, lanes 3
and 4). Treatment with transfection reagent oligo-
fectamine alone(X) or with control blank recombinant
retroviral vector (C0) had almost no effect (Figure 6C,
lanes 1 and 2).
Downregulation of CDC2 induces G2/M arrest in SHG-44 
cells
As CDC2 is essential for G2/M transition, cell cycle distri-
bution of recombinant C1- or C3-treated cells was ana-
lyzed using a FACScan flow cytometer. After incubation
for 48 h with 8 μg of recombinant C1 or C3, 15.8% and
21.1% of SHG44 cells were arrested in G2/M phase,
respectively, versus 3.9% of control SHG44 cells located
in G2/M phase. There was no G2/M arrest in cells treated
with lipofectamine (X) alone or cells treated with blank
retroviral vector (C0) (Figure 7).
Treatment with recombinant C1 or C3 triggers apoptosis 
in SHG-44 cells
In order to examine whether recombinant C1- or C3-
treated cells further led to apoptosis, the treated SHG44
cells were stained with annexin V and propidium iodide
(PI) and analyzed by flow cytometry. After incubation
with recombinant C1 or C3 for 48 h, 27.84% (C1) and
36.52% (C3) of SHG-44 cells were annexin V-positive
(early stage of apoptosis), versus 3.97% in lipofectamine
(X) alone and 4.39% in blank retroviral vector (C0)
treated SHG44 cells (Figure 8).
Therapeutic potential of CDC2 deletion on human 
gliomas: in vivo studies
Due to the strong inhibitory effect demonstrated ex vivo,
recombinant C3 was selected for viral packaging. The
impact of recombinant C3 retrovirus on xenogeneic graft
tumors was examined in vivo. Virus titer was 2.15 × 107
RCFU (relative colony forming unit). Xenogeneic graft
Immunoreactive score of CDC2/CyclinB1 in different grade  brain tumor and normal brain tissues Figure 4
Immunoreactive score of CDC2/CyclinB1 in different grade 
brain tumor and normal brain tissues. A-I: CDC2 immunohis-
tochemical images, J-R: CyclinB1 immunohistochemical 
images. CDC2/CyclinB1 was expressed in the cytoplasm of 
tumour cells. A/J: Normal adult brain tumor (-); B/K: Poly-
cystic astrocytoma (-); C/L: Fibrillary astrocytoma (+); D/M: 
Anaplastic Astrocytoma (++); E/N: medulloblastoma (+++); 
F/O: SHG44 multicellular tumor spheres (+++); G/P: GBM 
multicellular tumor spheres (+++); H/Q: Neural stem cell 
spheres (-); I/R: Brain tumor stem cells spheres (-).BMC Cancer 2008, 8:29 http://www.biomedcentral.com/1471-2407/8/29
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tumors treated with saline as control grew rapidly. In con-
trast, except tumor NO12, 15, 16, weight and volume of
other xenogeneic graft tumors treated with recombinant
C3 retrovirus were significantly reduced (Figure 9). Immu-
nohistochemistry indicated that the reduction in the per-
centage of CDC2 positive cells of the tumors was
correlated to the ratio of tumor shrinkage. In contrast, the
percentage of TUNEL positive cells was inversely propor-
tional to the ratio of tumor shrinkage (Figure 10). In addi-
tion, compared with animals treated with PBS, treatment
with recombinant C3 retrovirus resulted in a significant
increase (P < 0.05) in animal survival (Figure 11).
Table 1: Expression rate of CDC2/CyclinB1 in 98 specimens
Specimens Case CDC2 expression (case) Percentage of 
Positive cells (%)
Negative (-) Weak Positive (+) Positive (++) Strong Positive 
(+++)
Normal adult brain 
tumor
1 1 9200 1 8 . 2
G r a d e  I 97200 2 2 . 2
Polycystic 
astrocytoma
76100
Choroid plexus 
papilloma
21100
Grade II 25 15 8 2 0 40.0
Fibrillary 
astrocytoma
16 11 4 1 0
Protoplasmic 
astrocytoma
32100
Gemistocytic 
astrocytoma
10100
Oligodendroglioma 4 1 2 1 0
Ependymoma 1 1 0 0 0
Grade III 23 7 8 5 3 69.6
Anaplastic 
Astrocytoma
1 8 6732
Anaplastic 
oligodendroglioma
20101
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Graph showing cell growth treated with recombinant C1,  C3, C4, blank retroviral vector (C0) and transfection reagent  oligofectamine alone (X) Figure 5
Graph showing cell growth treated with recombinant C1, 
C3, C4, blank retroviral vector (C0) and transfection reagent 
oligofectamine alone (X).BMC Cancer 2008, 8:29 http://www.biomedcentral.com/1471-2407/8/29
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Discussion
Human glioma is the most common and aggressive pri-
mary brain cancer with mean patient survival, even with
aggressive treatments, including surgery, radiation ther-
apy, and chemotherapy, is typically 12 months or less [8].
Despite progress in research on the molecular aspects of
malignant gliomas, the prognosis of these brain tumors
continues to be dismal, partly because mechanisms
responsible for gliomagenesis and progression remain
elusive. In recent years, Ink4a-Arf, KRas, PDGF, PETN, RB,
c-Myc and TP53, have been implicated in the pathogene-
sis and progression of gliomas [15-20], mostly with
respect to cell cycle control and signal transduction
[21,22]. However, a few studies have reported the molec-
ular mechanism of CDC2/CyclinB1 implicated in gliom-
agenesis. CDC2 exerts protein kinase activity by
constructing a complex with cyclin A, cylin B, and
p13suc1 [23,24]. It is known as an active sub-unit of the
M-phase promoting factor (MPF) and the M-phase spe-
Downregulation of cdc2 induces G2/M arrest in SHG-44 cells Figure 7
Downregulation of cdc2 induces G2/M arrest in SHG-44 
cells. SHG44 cells treated with recombinant C1 or C3 were 
arrested in G2/M phase. There was no G2/M arrest in cells 
treated with blank retroviral vector (C0) and transfection 
reagent oligofectamine alone (X). (n = 3)
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Reduction of CDC2 mRNA and protein in SHG44 cell lines  by recombinant C1 or C3 Figure 6
Reduction of CDC2 mRNA and protein in SHG44 cell lines 
by recombinant C1 or C3. A, B, RT-PCR analysis: SHG44 
cells were treated with recombinant C1 or C3, C4, blank 
retroviral vector (C0) and transfection reagent oligo-
fectamine alone (X) for 48 h, β-actin served as an equal load-
ing control. C, Western blot analysis, the membrane was 
stained with antibodies against CDC2 and GAPDH. The lat-
ter served as an equal loading control.
Downregulation of cdc2 induces apoptosis in SHG-44 cells Figure 8
Downregulation of cdc2 induces apoptosis in SHG-44 cells. 
Graph shows the cell apoptosis treated with recombinant C1 
or C3, C0 and X. (n = 3)
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cific histone H1 kinase [25]. Furthermore, CDC2 also
plays a role in phosphorylating the retinoblastoma gene
product, which regulates the cells cycle by restricting DNA
replication [26] at G2/M transition [27]. Appropriate reg-
ulation of MPF is essential for the entry into mitosis.
Increasing results demonstrate that CDC2/CyclinB1 is
involved in checkpoint control, and that its dysregulation
could contribute to chromosomal instability in cancer
cells through an alteration of spindle checkpoint [28].
p53 gene inhibits cell cycle-dependent expression of
CDC2 and Cyclin B1 and consequently inhibits CDC2
kinase [28]. Our data indicated CDC2/CyclinB1 was over-
expressed in SHG44 and U251 with p53 mutations. Inves-
tigations to date have demonstrated that CDC2/CyclinB1
expression is likely to be correlated with the malignant
potential of human tumors [29-31]. Bodey B et al discov-
ered that the expression of CDC2 could become a novel
cell proliferation marker in childhood brain tumors [32].
Hence, overexpression of CDC2/CyclinB1 can promote
the heterogeneity and malignancy of tumor.
The reason why we chose CDC2/CyclinB1 as a target gene
was due to our previous findings that expression level of
CDC2 increased with the progression of the malignancy
when ganglioglioma transformed into gliobastona multi-
forme in the same patient [33]. In order to demonstrate
the relation in large-scale clinical cases, we constructed
human glioma tissue microarrays (TMA). The result of
TMA provides the first evidence that expression level of
CDC2/CyclinB1 increased with the progression of the
malignancy, suggesting that CDC2/CyclinB1 might be of
molecular significance in the progression of human glio-
mas.
We inhibit MPF activation by down-regulation of CDC2
to learn its function in human malignant glioma.
Although various inhibitors of CDC2 have been tested as
Survival of nude mice after intracranial injection of recom- binant C3 retrovirus into established SHG44 gliomas Figure 11
Survival of nude mice after intracranial injection of recom-
binant C3 retrovirus into established SHG44 gliomas. SHG44 
were implanted into the frontal lobe of nude mice. After 3 
days, tumors were injected with a single dose of recombinant 
C3 retrovirus or PBS (n = 8/group). Compared with animals 
treated with PBS (dash line), a significant increase in survival 
occurs in those treated with recombinant C3 retrovirus 
(solid line) (p < 0.05).
Injection of recombinant retrovirus significantly decreased  xenogeneic graft tumor volume Figure 9
Injection of recombinant retrovirus significantly decreased 
xenogeneic graft tumor volume. The upper row in the pic-
tures show xenogeneic graft tumor specimens treated with 
saline as control. The lower row show xenogeneic graft 
tumor specimens treated with recombinant C3 retrovirus. 
The lower quartile, median and the upper quartile is 57.6 mg, 
79.8 mg, 124.7 mg, respectively in control. The lower quar-
tile, median and the upper quartile is 18.1 mg, 33.5 mg and 
42.7 mg respectively in treated (P = 0.003, n = 8).
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Immunohistochemistry of tissue microarray (magnification  400×) Figure 10
Immunohistochemistry of tissue microarray (magnification 
400×). Immunoreactivities of CDC2 (A-C) and TUNEL (D-F) 
in xenogeneic graft tumor specimens were examined. IRS of 
CDC2 are negative in tumors treated with recombinant C3 
retrovirus (-) (A); positive in tumors treated with saline (++) 
(B); also positive in NO.12 tumor (C). IRS of TUNEL are 
positive in tumors treated with recombinant C3 retrovirus 
(++) (D); negative in tumors treated with saline (-) (E); also 
negative in NO.12 tumor (-) (F).
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potential candidates for tumor therapy, most of the inhib-
itors targeting CDC2 lack specificity [34,35]. RNAi is
viewed as a powerful tool to define gene function, and a
novel therapeutic strategy for treatment of human dis-
eases and conditions including cancer [36]. We demon-
strated that inhibition of CDC2 was an effective and
specific approach to inhibit the enzymatic activity of MPF,
to inhibit proliferation of human malignant glioma cells
ex vivo and suppress tumor growth in vivo. Our findings
suggest that recombinant retrovirus expressing shRNAs,
with its ability to down-regulate CDC2, has potential to
serve as a therapeutic agent in the treatment of human
malignant gliomas.
Cell cycle analysis indicated that cells transfected with
recombinant C1 or C3 were blocked in G2/M phase. This
arrest in G2/M phase likely contributes to the observed
anti-proliferative and antitumor effects in recombinant
C1- or C3-treated tumor cells and xenograft models. In
vivo, although the size of most recombinant C3-treated
human xenogeneic graft gliomas was reduced markedly,
no tumor disappeared as shown ex vivo. Immunohisto-
chemistry also confirmed that inhibition of tumor growth
correlated with CDC2 suppression. This indicates that
extensive and effective inhibition of CDC2 expression is
the key to successful therapy. The approach of directly
injecting recombinant retrovirus into the tumor through
multi-sites and different time points was unsuccessful
because the virus was unable to infect all tumor cells.
Improvement of the vector and transport approach is war-
ranted to circumvent the problem, thus gaining success in
cancer gene therapy.
It is now widely believed that most tumors including
glioblastoma arise from multipotent stem cells, as they
have the long lifespan that is required for the accumula-
tion of the many genetic alterations that are found in most
cancers [37]. Recent isolation and characterization of
brain tumor-initiating cells supports the concept that
transformed neural stem cells may seed gliomas [38].
However, the expression of CDC2 was both negative in
brain tumor stem cell spheres and neural stem cell
spheres. CDC2 was negative in differentiated cells of neu-
ral stem cells, versus overexperssion in differentiated cells
of brain tumor stem cells (data not show). Thus, overex-
pression of CDC2 was facilitative but not an initial factor
of gliomagenesis. To cure human gliomas, we need to
simultaneously target both tumor stem cells and prolifer-
ated tumor cells.
Conclusion
Using sensitive immunohistochemical methods and a
large, representative material, we found that the positive
expression rates of CDC2/CyclinB1 were positively corre-
lated with the pathologic grades of human gliomas. Over-
expression of CDC2 could promote oncogenesis and
progression of human gliomas whereas the downregula-
tion of CDC2 expression could inhibit the proliferation,
induce G2/M arrest, and trigger apoptosis in human glio-
mas. Therefore, CDC2 could become a potential target on
gene therapy of human gliomas.
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